Reversing an earlier decision, European regulators recommended that the Alzheimer’s therapy Leqembi should be approved ...
1d
Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced a positive opinion has been received from the Committee for Medicinal ...
The European Union's drugs regulator has recommended approval for Eisai and Biogen's Alzheimer's drug Leqembi. This marks a ...
and are at increased risk of developing Alzheimer’s disease. Those with one copy are at increased risk too. Leqembi, which ...
Eisai (ESAIY) and Biogen (BIIB) announced that a positive opinion has been received from the Committee for Medicinal Products for Human Use of ...
The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback